Tag: diabetes

FDA Warns over Risks Using Unapproved Devices for Diabetes Management

fda
The U.S. Food and Drug Administration is warning patients and health care professionals of risks associated with the use of unapproved or unauthorized devices for diabetes management, including contin...

Allergan Announced the Expansion of the PLEDGE Program in Diabetic Gastroparesis

allergan
Allergan plc announced the expansion of the PLEDGE program with a fifth study now evaluating relamorelin, an investigational, ghrelin agonist being studied for the treatment of diabetic gastroparesis ...

Harvard-led Research Boosts Cell Therapy for Diabetes

diabetes drugs
A team of researchers led by Harvard University scientists has improved the laboratory process of converting stem cells into insulin-producing beta cells, using biological and physical separation meth...

AstraZeneca Qternmet XR Approved in the USA

The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise t...

Forxiga Got Another Approval

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). Elisabeth Björk, Senio...

First Approved AZ’s Med for Type-1 Diabetes

Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes. The European Com...

Teva to Launch Generis of Novo Nordisk Non-Insulin Med

Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently...

AZ’s Diabetes Drug Reduces Heart Failure Risk

Farxiga reduced hospitalisation for heart failure regardless of ejection fraction status. Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxi...

Pfizer to License AnTolRx Type 1 Diabetes Therapy

AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. has exercised the option granted under a June 2016 agreement to license an immune tole...

Lilly Launches Low-Priced Insulin

Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price. Reinforcing the commitment to lower out-of-pocket costs for people who need insulin, Eli L...

Novo Nordisk Submitted Label Updates for its Insulin Aspart

Novo Nordisk announced that it has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (fast-acting insulin aspart), seeking approva...

EMA Comittee Backs Sanofi and Lexicon Diabetes Med

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of Zynquista™ (sotagliflozin), developed by Sanofi a...

First Human Study of Pill Designed to Replace Injections

Safety and tolerability of RaniPill™ Capsule in humans advances oral delivery of injectable biologic drugs. The first human study of a pill designed to replace injections of biologics is today bein...

Boehringer and Lilly’s 2 Diabetes Drug Met Endpoint

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined a...

EMA Recommended AstraZeneca’s Type I Diabetes Drug

AstraZeneca’s Forxiga (dapagliflozin) has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin i...

Novo Nordisk Expects Fast-Track Review for New Semaglutide

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US. The FDA grants ...